PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsadenoma
MeSH D000236 - adenoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009375:Glandular and epithelial neoplasms
0 Companies
0 Drugs
Success rate
D000236: 
Adenoma
$
Success rate
D000237:Basophil adenoma
0 Companies
0 Drugs
Success rate
D000238:Chromophobe adenoma
0 Companies
0 Drugs
Success rate
D000239:Acidophil adenoma
0 Companies
0 Drugs
Success rate
D000314:Adrenal rest tumor
0 Companies
0 Drugs
Success rate
D001079:Apudoma
0 Companies
0 Drugs
Success rate
D002759:Bile duct adenoma
0 Companies
0 Drugs
Success rate
D003537:Cystadenoma
0 Companies
0 Drugs
Success rate
D006607:Sweat gland adenoma
0 Companies
0 Drugs
Success rate
D007516:Islet cell adenoma
0 Companies
0 Drugs
Success rate
D008654:Mesothelioma
$
Success rate
D008949:Pleomorphic adenoma
0 Companies
0 Drugs
Success rate
D015175:Prolactinoma
0 Companies
0 Drugs
Success rate
D018248:Liver cell adenoma
0 Companies
0 Drugs
Success rate
D018249:Oxyphilic adenoma
0 Companies
0 Drugs
Success rate
D018253:Villous adenoma
0 Companies
0 Drugs
Success rate
D018254:Adenomatoid tumor
0 Companies
0 Drugs
Success rate
D018255:Pulmonary adenomatosis
0 Companies
0 Drugs
Success rate
D018256:Adenomatous polyps
0 Companies
0 Drugs
Success rate
D049912:Growth hormone-secreting pituitary adenoma
0 Companies
0 Drugs
Success rate
D049913:Acth-secreting pituitary adenoma
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaCabergoline Cabergoline  2007-03-07   
Octreotide Octreotide  2023-12-05   
PadagisBromocriptine Bromocriptine  2008-10-01   
IngenusCabergoline Cabergoline  2018-08-01   
MylanBromocriptine Bromocriptine  2005-04-04   
Cabergoline Cabergoline  2013-12-02   
Octreotide Octreotide  2011-02-10   
SandozBromocriptine Bromocriptine  1998-01-13   
NovartisOctreotide Sandostatin  1988-10-21 $1,321 M Q2/21-Q2/24 
PfizerCabergoline Dostinex  1996-12-23   
Zydus TherapeuticsBromocriptine Bromocriptine  2008-07-30   
Sun Pharmaceutical IndustriesOctreotide Octreotide  2008-03-04   
ApotexCabergoline Cabergoline  2013-03-08   
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
0%
0/1
Phase 2
100%
6/6
Phase 3
45%
5/11
Approved: 4Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Mylan
Novartis
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use